E.ON, EnBW, RWE - German utilities: Mixed bag of 1H25 results

German utilities RWE, EnBW and E.ON published their 1H25 financial performance, which we would qualify as a mixed bag of results. Lower trading, lower power volumes and prices impacted RWE and EnBW the most. On the other hand, with its business model skewed toward network operations, E.ON performed strongly in the first six months of 2025. The latest financial results and strategic developments confirmed our fundamental views on the issuers. E.ON remains our favourite German utility but some of its bonds continue to trade too tight. RWE remains our least preferred name amongst the three and it...

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 08/15/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 15/08/2025

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...